Medicines planning
47 results
Applied filters
The licence and supporting evidence for tocilizumab biosimilar
6 March 2026Two licensed tocilizumab biosimilars are available: Tyenne and Avtozma. Learn about the licensed indications, supporting evidence and key differences.
Preparing to use ustekinumab biosimilar
29 July 2025Introducing biosimilar ustekinumab needs planning. Work with the multidisciplinary team to ensure familiarity with the area and develop an implementation plan.
The licence and supporting evidence for ustekinumab biosimilars
29 July 2025Ustekinumab biosimilars (Pyzchiva, Steqeyma, Uzpruvo, Wezenla) are licensed. Learn about indications, formulations, supporting evidence and differences.
Good governance when implementing ustekinumab biosimilar
29 July 2025Governance should consider processes for approval, procurement and supply, prescribing and administration, monitoring, and pharmacovigilance.
Exagamglogene autotemcel (Casgevy®)
13 February 2026This document highlights key areas where Chief Pharmacists should focus pharmaceutical expertise prior to implementation of exagamglogene autotemcel.
Using our annual medicines planning publication, Prescribing Outlook
28 October 2024Users should be aware of the constraints and assumptions in creating Prescribing Outlook, as well as their responsibilities for use.
National Homecare Medicines Committee regional contacts
12 May 2025Contact details of the homecare regional specialists within the UK who sit on the National Homecare Medicines Committee (NHMC).
Preparing to use golimumab biosimilar
9 January 2026One golimumab biosimilar (Gobivaz) is available. We offer general information and implementation advice.
Preparing to use aflibercept 2mg biosimilar
3 February 2026Aflibercept 2mg biosimilars for use in ophthalmology are available for NHS use. We offer general information and implementation advice.
Understanding biosimilar and generic market entry
12 September 2025New medicines have several protections against competition. Other factors influence availability of biosimilars or generics after loss of exclusivity.